AVENTURA, FL--(Marketwire - February 21, 2012) - bioRASI, a full service, global Contract Research Organization (CRO), announced today that they will participate at the 2012 GPhA Annual Meeting in Orlando, Florida on February 22 - 24th. bioRASI will be exhibiting at booth #6 and will showcase its strategies and solutions for optimizing ophthalmic drugs development programs.
bioRASI will be introducing a new ophthalmology issue in their White Papers Series highlighting clinical endpoint ANDA Program Optimization techniques for the generics and specialty pharmaceutical industry.
"The share of ophthalmic drugs within most generic pipelines has been growing rapidly. bioRASI has emerged as the leader in conducting ophthalmology clinical studies," said Dr. Boris Reznik, Chairman of bioRASI. "Our Ophthalmology Program Management team consists of several MDs and MDs/PhDs in ophthalmology. This background coupled with many years of ophthalmic clinical trials experience makes bioRASI's ability to optimize these programs second to none."
bioRASI publishes the white papers several times a year, addressing and analyzing different aspects of optimization, and making them available on their website, at marketing and technical conferences and through other established electronic publishing services.
bioRASI is a Full Service Global CRO. Its Generics Division is uniquely focused on clinical endpoint ANDA and 505(b)(2) programs. This experience and expertise allow bioRASI to facilitate obtaining FDA approvals by delivering high quality regulatory and clinical strategies, solutions and services, while saving their clients critical time. bioRASI's services include program management, regulatory, clinical, data management and analysis, compliance and audit. bioRASI leverages its unique access to the world's largest facilities and patient populations in the U.S., Europe and Asia to achieve unparalleled scientific, clinical and business results at significantly lower costs. bioRASI is headquartered in Aventura, FL and has regional offices across in the U.S and overseas.